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Background:  Recombinant  hepatitis  B  surface  antigen  (HBsAg)  was  used  as a model  antigen  to  evaluate
persistence  of  cellular  and  humoral  immune  responses  when  formulated  with  three  different  Adjuvant
Systems  containing  3-O-desacyl-4′-monophosphoryl  lipid  A  (MPL)  and  QS-21,  in  an  oil-in-water  emulsion
(AS02B and  AS02V),  or with  liposomes  (AS01B).
Methods:  This  is  an  open,  4-year  follow-up  of  a  previous  randomised,  double-blind  study.  Healthy  subjects
aged  18–40  years  received  three  vaccine  doses  on  a month  0, 1, 10 schedule  and  were  initially  followed
for  18  months.  A  total  of  93 subjects  (AS02B: n = 30;  AS02V: n = 28; AS01B: n  =  35)  were  enrolled  in this
follow-up  and  had  an  additional  blood  sample  taken  at Year  4 (NCT02153320).  The primary  endpoint
was  the  frequency  of HBsAg-speciﬁc  CD4+ and  CD8+ T-cells  expressing  cytokines  upon  short-term  in  vitro
stimulation  of  peripheral  blood  mononuclear  cells  with  HBsAg-derived  peptides.  Secondary  endpoints
were  anti-HBs  antibody  titres  and frequency  of  HBsAg-speciﬁc  memory  B-cells.
Results: A  strong  and  persistent  speciﬁc  CD4+ T-cell  response  was  observed  at Year  4 in all  groups.  HBsAg-
speciﬁc  CD4+ T-cells  expressed  mainly  CD40L  and  IL-2,  and  to  a lesser  extent  TNF-  and  IFN-.  HBsAg-
speciﬁc  CD8+ T-cells  were  not  detected  in  any  group.  A high,  persistent  HBsAg-speciﬁc  humoral  immune
response  was  observed  in all  groups,  with  all subjects  seroprotected  (antibody  titre  ≥10 mIU/mL)  at  Year
4.  The  geometric  mean  antibody  titre  at Year  4 was  above  100,000  mIU/mL  in  all  groups.  A  strong  memory
B-cell  response  was observed  post-dose  2, which  tended  to increase  post-dose  3  and  persisted  at  Year  4
in all  groups.
Conclusion:  The  MPL/QS-21/HBsAg  vaccine  formulations  induced  persistent  immune  responses  up to  4
years after  ﬁrst  vaccination.  These  Adjuvant  Systems  offer  potential  for  combination  with  recombinant,
synthetic  or  highly  puriﬁed  subunit  vaccines,  particularly  for vaccination  against  challenging  diseases,  or
in speciﬁc  populations,  although  additional  studies  are  needed.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: AS, adjuvant system; DTH, delayed-type hypersensitivity; ELISPOT, e
epatitis B surface antigen; HIV, human immunodeﬁciency virus; ICS, intracellular cyt
onophosphoryl lipid A; PBMC, peripheral blood mononuclear cells; QS-21, Quillaja sapo
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nzyme-linked immunosorbent spot; GMT, geometric mean antibody titre; HBsAg,
okine staining; IFN, interferon gamma; IL2, interleukin 2; MPL, 3-O-desacyl-4′-
naria Molina fraction 21; TNF, tumour necrosis factor alpha.
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. Introduction
GlaxoSmithKline (GSK) Vaccines have developed a series of
djuvant Systems (AS) containing two potent immunostimulants,
-O-desacyl-4′-monophosphoryl lipid A (MPL) and QS-21 (Quillaja
aponaria Molina fraction 21; Antigenics Inc, a wholly owned sub-
idiary of Agenus Inc., Lexington, MA,  USA), which in addition to
romoting strong and persistent antibody responses, potentiate
peciﬁc cellular immunity [1]. Such Adjuvant Systems may  be use-
ul to enhance potency in vaccines against pathogens that cause
omplex acute or chronic disease (e.g., human immunodeﬁciency
irus (HIV), Plasmodium falciparum,  Mycobacterium tuberculosis,
r herpes zoster in older adults [2,3]), in therapeutic vaccines
e.g., cancer vaccine targeting MAGE-A3 [4]), or to induce immune
esponses in populations that do not adequately respond to non-
r alum-adjuvanted vaccines (e.g., herpes zoster and Streptococcus
neumoniae in older adults [5–7]).
Administration of vaccines containing both MPL  and QS-21
ave resulted in high antigen-speciﬁc antibody and CD4+ T-
ell responses in preclinical and clinical studies [8–18]. The
ext challenge in Adjuvant System research is to evaluate
ffects on the magnitude and quality of immune responses over
he longer term, particularly with regard to cytokine produc-
ion by polyfunctional T-cells. To our knowledge, no long-term
mmunological studies of adjuvanted vaccines have been pub-
ished.
In the present 4-year follow-up to a previously reported study
8], we evaluated the persistence of immune responses using hep-
titis B surface antigen (HBsAg) as a model antigen formulated
ith three different MPL  and QS-21-containing Adjuvant Systems:
S02B, AS02V, and AS01B. The primary objective was to eval-
ate the persistence of cellular immune responses in terms of
BsAg-speciﬁc CD4+ and CD8+ T-cells. Secondary objectives were
o evaluate persistence of anti-HBs antibodies and HBsAg-speciﬁc
-cell memory.
. Methods
.1. Study design and participants
This was an open, 4-year follow-up of a randomised, double-
lind study conducted at two centres in Belgium [8]. No additional
accines were administered in this follow-up study. There was a
ingle visit at Year 4 at which a blood sample for immunogenicity
ssays were taken. No further follow-up is planned after this 4-
ear time point. Samples were collected between September and
ctober 2005. All subjects gave written informed consent for the
ollow-up evaluation and the study was approved by the local ethics
ommittees according to the Declaration of Helsinki. The study is
egistered with ClinicalTrials.gov (number NCT02153320).
In the primary vaccination study, healthy male and female sub-
ects were vaccinated on a month 0, 1, 10 schedule with three doses
f recombinant HBsAg (20 g) formulated with the following Adju-
ant Systems: AS02B (100 g MPL  and 100 g QS-21 in full dose
f oil-in-water emulsion), AS02V (50 g MPL  and 50 g QS-21 in
educed amount of modiﬁed oil-in-water emulsion), AS01B (50 g
PL  and 50 g QS-21 in liposomes), or CpG 7909 class B oligonu-
leotide (500 g in saline buffer) [8]. Participants were recruited
rom the 131 subjects who completed the primary study [8], who
ad been randomised to one of the three groups that received
ecombinant HBsAg formulated with AS02B, AS02V or AS01B and
ho consented to follow-up evaluation. Subjects who received
BsAg formulated with CpG were not enrolled in this 4-year follow-
p because of their poor cellular immune responses up to Week 78
8]. 33 (2015) 1084–1091 1085
A delayed-type hypersensitivity (DTH) skin test involving
intradermal injection of 2 g puriﬁed HBsAg was performed
at Week 78 of the primary vaccination study, as reported
previously [8]. This test was  stopped prematurely because of
reactogenicity [8], therefore, some subjects enrolled in the 4-
year follow-up had received the DTH challenge and some had
not.
2.2. Immunological assays
2.2.1. HBsAg-speciﬁc CD4+ and CD8+ T-cells
HBsAg-speciﬁc CD4+ and CD8+ T-cell responses were evaluated
at Week 78 (using existing samples collected during the double-
blind study) and at Year 4, using Intracellular Cytokine Staining
(ICS) as described for the previous study [8]. Brieﬂy, following
short-term in vitro stimulation of peripheral blood mononuclear
cells (PBMCs) with a pool of peptides covering the entire sequence
of the recombinant HBsAg, cells were processed by conventional
immunoﬂuorescence and analysed by ﬂow cytometry to measure
the frequency of HBsAg-speciﬁc CD4+ or CD8+ T-cells secreting
CD40L, interleukin 2 (IL2), tumour necrosis factor alpha (TNF),
and/or interferon gamma  (IFN) (frequencies expressed per million
cells).
2.2.2. Serum anti-HBsAg antibodies
Anti-HBsAg antibody titres were evaluated at Year 4 by AxSYM®
AUSAB® assay (Abbott Laboratories). For the cohort of subjects
enrolled in this follow-up, anti-HBsAg antibody titres previously
measured at Day 0 and Weeks 6, 46, 48 and 78 are also summarised.
2.2.3. HBsAg-speciﬁc memory B-cells
HBsAg-speciﬁc B-cell responses were evaluated at Day 0, Weeks
6, 46, 48 and 78 (using existing samples collected during the
double-blind study) and at Year 4. Memory B-cells were induced
to differentiate into plasma cells following in vitro cultivation of
PBMC with unmethylated DNA (CpG2006 at 3 g/mL, Eurogen-
tec, Belgium) for 5 days. In vitro-generated antigen-speciﬁc plasma
cells were enumerated using the enzyme-linked immunosorbent
spot (ELISPOT) assay [19]. In vitro-generated plasma cells were
incubated in culture plates previously coated with 5 g/mL of
antigen or with 100 L of anti-human IgG at 1 g/mL (Goat
anti-human Afﬁnipure, Jackson Laboratories) in order to enumer-
ate speciﬁc antibody or IgG secreting plasma cells, respectively.
The antibody/antigen spots formed were detected by a conven-
tional immunoenzymatic procedure. Frequencies of HBsAg-speciﬁc
memory B-cells are expressed per million IgG-producing memory
B-cells.
2.3. Safety
Reactogenicity and safety of the vaccine formulations up to
Week 78 were described in the earlier publication [8] and no addi-
tional safety evaluation was  done at Year 4.
2.4. Statistical methods
The total cohort included all subjects enrolled in this follow-up
study. For each speciﬁed endpoint, those subjects for whom val-
idated assay results were available were included in the analysis
of that endpoint. The number of subjects included in analyses dif-
fers by endpoint as validated assay results were not available for all
subjects for every endpoint. Data are summarised using descriptive
statistics. No statistical comparisons were made.
1086 G. Leroux-Roels et al. / Vaccine 33 (2015) 1084–1091
ipant
2
i
m
H
o
o
t
b
2
(
w
t
g
c
t
2
h
r
a
t
d
3
3
i
g
8
a
o
o
t
(
3
C
a
a
immune response was observed at Year 4 (Fig. 5). GMTs increased
after each vaccine dose and peaked two weeks post-dose 3 (Week
48), with GMTs >750,000 mIU/mL in all groups. Thereafter, GMTs
gradually declined, although there was less than 1 log reduction in
Fig. 2. Frequency of HBsAg-speciﬁc CD4+ T-cells cells expressing at least two mark-
ers (among CD40L, IL2, TNF and IFN) per million CD4+ T-cells upon short-termFig. 1. Flow of partic
.4.1. Cell-mediated immune responses
The frequency of HBsAg-speciﬁc CD4+ and CD8+ T-cells express-
ng at least two markers among CD40L, IL2, TNF, and IFN per
illion CD4+ or CD8+ T-cells, respectively, and the frequency of
BsAg-speciﬁc memory B-cells per million IgG-producing mem-
ry B-cells, are summarised. The cytokine co-expression proﬁle
f HBsAg-speciﬁc CD4+ and CD8+ T-cells is also summarised. Log-
ransformation of the frequency of HBsAg-speciﬁc cells was  applied
y setting all values of 0 equal to 1.
.4.2. Serum anti-HBsAg antibodies
Seroprotection rates and geometric mean antibody titres
GMTs) with 95% conﬁdence intervals (CIs) were calculated. GMTs
ere calculated by taking the anti-log of the mean of the log titre
ransformations. Antibody titres below the cut-off of the assay were
iven an arbitrary value of half the cut-off for the purpose of GMT
alculation. Seroprotection was deﬁned as an anti-HBsAg antibody
itre ≥10 mIU/mL.
.4.3. Post-hoc analysis according to delayed-type
ypersensitivity DTH challenge
To investigate the impact of the DTH challenge on immune
esponses at Year 4, exploratory dotplots of immune responses
t Week 78 versus Year 4 were produced for the subpopula-
ions of subjects who received the DTH challenge and those who
id not.
. Results
.1. Study population
A total of 93 subjects were enrolled in this 4-year follow-up (30
n the AS02B group, 35 in the AS01B group and 28 in the AS02V
roup) (Fig. 1). The DTH challenge at Week 78 was performed on
3 of these subjects (26 in the AS02B group, 30 in the AS01B group
nd 27 in the AS02V group).
The three groups were comparable with respect to age, with an
verall mean age of 28.1 years (range 23–44 years). Overall, 65%
f the subjects were male (between 57% and 70% depending on
he group) and the population was predominantly white Caucasian
98%).
.2. HBsAg-speciﬁc CD4+ and CD8+ T-cellsFollowing in vitro stimulation of PBMCs, a strong HBsAg-speciﬁc
D4+ T-cell response (i.e., cells expressing at least two  markers
mong CD40L, IL2, TNF and IFN) was observed at Week 78
nd Year 4 in all three groups (Fig. 2). The median frequencies ofs through the study.
HBsAg-speciﬁc CD4+ T-cells expressing at least two  markers per
million CD4+ T-cells at Week 78 and Year 4, respectively, were
3400 and 2433 for AS02B, 2227 and 2189 for AS01B, and 1338 and
1093 for AS02V.
The polyfunctional HBsAg-speciﬁc CD4+ T-cell response per-
sisted between Week 78 and Year 4 (Fig. 3). At Year 4,
HBsAg-speciﬁc CD4+ T-cells expressed mainly CD40L and IL2, and
to a lesser extent TNF and IFN, with a similar proﬁle in each group
(Fig. 4).
No signiﬁcant levels of HBsAg-speciﬁc CD8+ T-cells could be
detected in any of the groups at Week 78 or at Year 4 following
in vitro stimulation of PBMCs with the HBsAg peptide pool (median
<40 HBsAg-speciﬁc CD8+ T-cells per million CD8+ T-cells per group).
3.3. Serum anti-HBsAg antibodies
In all three groups, a high and persistent HBsAg-speciﬁc humoralin  vitro stimulation of peripheral blood mononuclear cells with a pool of peptides
covering the entire sequence of the recombinant HBsAg at Week 78 and Year 4. The
box  represents the upper and lower quartiles; the horizontal line within the box
represents the median value; the whiskers represent the minimum and maximum
values.
G. Leroux-Roels et al. / Vaccine
Fig. 3. Mean number of HBsAg-speciﬁc CD4+ T-cells per million CD4+ T-cells in
each group expressing 1, 2, 3 or 4 markers (among CD40L, IL2, TNF and IFN) at
Week 78 and Year 4 upon short-term in vitro stimulation of peripheral blood mono-
nuclear cells with a pool of peptides covering the entire sequence of the recombinant
HBsAg. Each pie chart is sized proportionally with regard to the total mean number
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remained remarkably high (GMT >100,000 mIU/mL), predicting anf  HBsAg-speciﬁc CD4+ T-cells per million CD4+ T-cells (mean number shown in
arentheses) with the AS02B group at Week 78 as the reference (100%).
MTs from post-dose 3 to Year 4 (estimated ratios of decline Week
8:Year 4 GMTs were 2.5–3.2 per year for each group). The rate of
ecline in antibody titres appeared slower for the period from Week
8 to Year 4 (ratio of 1.4 per year for each group) compared with the
eriod from Week 48 to Week 78 (ratio of 3.2–4.1 per year for each
roup). At Year 4, all subjects were still seroprotected (antibody
itre ≥10 mIU/mL) and GMT  values were >100,000 mIU/mL in all
roups, which was higher than the GMT  values observed post-dose
 (Week 6).
.4. HBsAg-speciﬁc memory B-cells
In all groups, the median frequency of peripheral HBsAg-speciﬁc
-cells tended to increase from pre-vaccination to two weeks post-
ose 2 (Week 6), and further increased two weeks post-dose 3
Week 48) (Fig. 6). There was good persistence of HBsAg-speciﬁc
-cells at Year 4. The median frequencies of HBsAg-speciﬁc B-cells
er million B-cells at Week 78 and Year 4, respectively, were 2618
nd 1804 for AS02B, 2719 and 1471 for AS01B, and 3588 and 1491
or AS02V.
The frequencies of peripheral HBsAg-speciﬁc B-cells post-dose
 (Week 48) in each group did not seem to be correlated with anti-
ody titres at later time points (Week 78 and Year 4), with Pearson’s
orrelation coefﬁcient (r) between 0.3 and 0.5 (Supplementary Fig.
).
.5. Impact of DTH challenge on persistence of immune responses
A post hoc exploratory analysis suggested that frequencies of
BsAg-speciﬁc CD4+ T-cells, CD8+ T-cells, memory B-cells, and
nti-HBsAg antibody concentrations were within the same range
t Year 4, when compared to Week 78 values, for those subjects
ho had the DTH challenge and those who did not (Supplemen-ary Figs. 2 and 3). The number of subjects who did not have the
TH challenge at Week 78 was small, which limited interpretation
f these data. 33 (2015) 1084–1091 1087
4. Discussion
GSK’s Adjuvant Systems were speciﬁcally developed to induce
strong and persistent cellular immune responses against vaccine
antigens, whilst maintaining a high antibody response and hav-
ing an acceptable safety proﬁle. The present study was undertaken
to evaluate the longer-term persistence of cellular and humoral
immune responses against a model antigen (recombinant HBsAg)
formulated with three MPL  and QS-21-containing Adjuvant Sys-
tems, AS02B, AS01B and AS02V. Results up to Week 78 of this
study (i.e., 18 months after ﬁrst vaccination) have been reported
previously, and showed that the three formulations induced high
levels of antibodies, strong and persistent CD4+ T-cell responses for
HBsAg, while cytolytic T-cells could be detected in some subjects
[8].
We now show that the humoral and cell-mediated immunity
elicited by the three MPL/QS-21 vaccine formulations persisted
up to 4 years after ﬁrst vaccination, with no observed differences
between the three formulations, although it should be noted that
this follow-up was  not designed nor powered to make formal
comparisons between groups. Previous results from earlier time
points showed that the AS01B formulation induced a stronger and
more persistent cell-mediated immune response to HBsAg than the
AS02B or AS02V formulations [8]. This could be related to different
interactions of these adjuvant components with the components
of the innate immune response against this antigen in the ﬁrst
weeks after vaccination. Although AS01 also showed improved
responses with other antigens against HIV, tuberculosis or malaria,
it is still important for each new vaccine to search for the best
antigen/adjuvant combination that achieves the desired immune
response against this speciﬁc pathogen in a speciﬁc population [1].
A high and sustained polyfunctional HBsAg-speciﬁc CD4+ T-cell
response (i.e., cells that coproduce more than one cytokine) was
induced by all three vaccine formulations following short-term
in vitro restimulation with HBsAg. Most of the HBsAg-speciﬁc CD4+
T-cells detected at Year 4 expressed both CD40L and IL2, with a
substantial proportion also expressing TNF and/or IFN.  This is
important as previous studies have shown that a polyfunctional
antigen-speciﬁc CD4+ T-cell response is required for sustained
protective immunity against various chronic infections, including
tuberculosis, malaria and HIV [20–23].
Similar to earlier time points [8], cytokine-producing HBsAg-
speciﬁc CD8+ T-cells were not consistently detected at Week 78
or Year 4 following short-term in vitro restimulation. This suggests
that either the frequency of CD8+ T-cells induced following vacci-
nation was below the limit of detection, that circulating levels of
speciﬁc CD8+ T-cells may  not accurately represent the total speciﬁc
CD8+ T-cell response, or that the vaccine-induced cytolytic activ-
ity observed at earlier timepoints [8] was CD4-mediated. The lack
of a speciﬁc CD8+ T-cell response was  also noted in other trials
with MPL/QS-21 adjuvanted vaccines using puriﬁed protein anti-
gens, e.g., malaria (RTS,S), tuberculosis (Mtb72), and HIV-1 (F4)
candidate vaccines [14,15,24,25]. This paucity of response was not
unexpected since the formulation of soluble antigen with MPL/QS-
21-containing Adjuvant Systems was designed to favour HLA-class
II mediated antigen presentation to CD4+ T-helper cells.
The three MPL/QS-21-adjuvanted vaccines induced a potent and
sustained humoral response. The ratios of magnitude of responses
at Week 78 versus Year 4 suggest more stability for cell-mediated
responses than humoral responses. Nonetheless, four years after
ﬁrst vaccination, all vaccine recipients had antibody titres indica-
tive of protection (≥10 mIU/mL) and anti-HBsAg antibody levelsexceptionally long duration of seroprotection. Comparisons across
studies should be treated with caution, in part due to differences
in vaccination schedules and study populations, but the decline in
1088 G. Leroux-Roels et al. / Vaccine 33 (2015) 1084–1091
Fig. 4. Frequency of HBsAg-speciﬁc CD4+ T-cells in each group at Year 4 expressing 1, 2, 3 or 4 markers (among CD40L, IL2, TNF and IFN) upon short-term in vitro stimulation
of  peripheral blood mononuclear cells with a pool of peptides covering the entire sequence of the recombinant HBsAg. Antigen-speciﬁc CD4+ T-cells were enumerated by
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f  CD4+ T-cells expressing markers per million CD4+ T-cells. The box represents th
alue;  the whiskers represent the minimum and maximum values.
nti-HBsAg antibody titres from post-dose 3 to 4 years after ﬁrst
accination with the vaccines formulated with the three MPL/QS-
1 Adjuvant Systems appeared less than previously reported with
ther vaccines which contain the same recombinant HBsAg adju-
anted with aluminium (i.e.,  Engerix B® in adolescents [26] and
winrix® in young adults [27]).pe as well as intracellular cytokine production. Results are expressed as frequency
er and lower quartiles; the horizontal line within the box represents the median
The kinetics of the HBsAg-speciﬁc memory B-cell response fol-
lowed a generally similar pattern to that of antibody production,
with frequencies tending to increase from pre-vaccination to two
weeks after the second dose and further increasing two weeks after
the third (booster) dose, followed by a gradual decline through
Week 78 and Year 4. However, frequencies of memory B-cells after
G. Leroux-Roels et al. / Vaccine
Fig. 5. Antibody response following vaccination at Weeks 0, 4 and 46 with 20 g of
HBsAg formulated with the AS02B, AS01B or AS02V Adjuvant Systems. Anti-HBsAg
antibodies were measured by AxSYM® AUSAB® assay (Abbott Laboratories) and are
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he booster vaccine dose at Week 48 did not seem to be indica-
ive of antibody titres at later time points. At the time of study
esign, memory B-cells were considered to be the major pool of
ntibody-secreting plasma cells [28], hence the planned testing
nd correlation analysis in our study. However, more recent stud-
es have shown that there is only a weak correlation between
emory B-cells and serum antibodies (e.g., depletion of memory
-cells in the plasma in patients with autoimmune disease leads
o only a minor reduction in antibodies [29]). It is now consid-
red that the major source of stable antigen-speciﬁc antibodies
n the serum is long-lived plasma cells often surviving in spe-
ialised niches in the bone marrow [30,31], rather than memory
-cells recirculating between the peripheral lymphoid tissues [32].
emory B-cells probably dictate the magnitude and kinetics of the
ig. 6. Frequency of HBsAg-speciﬁc memory B-cells following in vitro cultivation of peri
ntigen-speciﬁc plasma cells by ELISPOT. Results are expressed as frequency of HBsAg-sp
nd  lower quartiles; the horizontal line within the box represents the median value; the 
he  frequency of HBsAg-speciﬁc B-cells was applied by setting all values of 0 equal to 1.W 33 (2015) 1084–1091 1089
antibody response following a booster dose (together with CD4+
T-cell help) [32].
The late timing of the booster dose at Week 46, together with
the immunostimulatory properties of the MPL/QS-21 Adjuvant Sys-
tems, may  have contributed to the particularly high cellular and
humoral responses observed. Another possible important inﬂuenc-
ing factor is the effect of a DTH skin test performed at Week 78
(involving intradermal injection of 2 g puriﬁed HBsAg [8]), which
may  have additionally boosted immune responses. However, no
blood samples were taken immediately after this DTH challenge,
or in the interval between Week 78 and Year 4, so it was not possi-
ble to determine the direct effect of this challenge on immunity.
Immune responses have been summarised for the total cohort,
regardless of whether the subject received the DTH challenge or
not. In an exploratory analysis, immune responses at Year 4 com-
pared to values reported at Week 78 appeared to be in the same
range for those subjects who  received the challenge and those who
did not, although numbers of unchallenged subjects were small,
limiting the conclusions that can be drawn.
The main limitation of this study is that the three Adjuvant
Systems were evaluated in a speciﬁc context using HBsAg as a
model antigen in healthy, naïve adults, therefore, ﬁndings may
not be directly applicable to other scenarios. Although studies
with MPL/QS-21 adjuvanted candidate vaccines against complex
or chronic diseases show promising results in terms of immune
response in HIV and tuberculosis infected subjects [33,34] and
demonstrated partial efﬁcacy against malaria [35], there is need
for additional studies in terms of protection against those and
other diseases in more diverse populations and assess longer term
effects. Secondly, we have not tracked any exposure risk factors
(transfusions, medical occupations, frequent syringe use) in the
trial cohorts. Therefore, we cannot exclude that any natural virus
challenges during this follow up period might have inﬂuenced the
levels of memory B-cell and T-cell activation. Other limitations are
that this was  an exploratory, descriptive study and no statistical
comparisons were done.In summary, three doses of MPL/QS-21 Adjuvant Systems
in combination with HBsAg induced high quality and persis-
tent humoral and cellular immune responses that persisted
at least 4 years after ﬁrst vaccination in healthy adults. These
pheral blood mononuclear cells with CpG for 5 days and subsequent detection of
eciﬁc B-cells per 106 IgG-producing memory B-cells. The box represents the upper
whiskers represent the minimum and maximum values. The log-transformation of
K: Week; Yr: year.
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djuvant Systems offer potential for combination with recombi-
ant, synthetic or highly puriﬁed subunit vaccines for vaccination
gainst challenging or chronic diseases, as therapeutic vaccines,
n immunotherapy, or for subjects with immune dysfunction such
s older adults, chronically diseased, or immunocompromised
ersons. However, additional studies are needed to assess the
mmunological and clinical effect of these adjuvants in combi-
ation with different antigens in different populations against
omplex diseases such as malaria, tuberculosis or HIV.
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